Recent & Archived News

Filter:

Bayer to Highlight New Research at ASCO GI 2018 Cancer Symposium
» more
Bayer Announces that Loxo Oncology, Inc., Initiates Rolling NDA Submission for Larotrectinib for the Treatment of TRK Fusion Cancers
» more
Bayer to Highlight New Research at ASH 2017
» more
Updated larotrectinib pediatric Phase I clinical trial data demonstrates response in TRK fusion cancers
» more
Phase III trial of radium Ra 223 dichloride in combination with abiraterone acetate and prednisone/prednisolone for patients with metastatic castration-resistant prostate cancer unblinded early
» more
Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority
» more
Bayer and Loxo Oncology to develop and commercialize two therapies that selectively target genetic drivers of cancer
» more
Bayer Announces BAY94-9027 Biologics License Application Accepted by U.S. Food & Drug Administration
» more
Bayer and the Society for Reproductive Investigation Collaborate to Advance Women's Healthcare Research
» more
Bayer Receives FDA Approval for Aliqopa™ (copanlisib) 60 mg vial for Injection in Adults with Relapsed Follicular Lymphoma after Two Prior Systemic Therapies
» more

Want even more Bayer news? Check out our Social Media & Blogs.